1Sweberg KP,Feffer M,Granger C.Candersartan in mortality and morbidity(CHARM)rational and design.Card fail 1999;5(3):276-82.
2Pitt B,Segal R,Martinis Z.Randomized trial of losartan versus capital in patients over 65 with heart failure.Lancet 1997;349(9054):747-55.
3Woo KS,Nicholls MG.High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese.Br J Chin Pharmacol 1995;40:141-4.
4Struthers AD.AngiotensinⅡ receptor antagonists for heart failure.Heart 1998;80:5-6.
5Collucci WS. Molecular and cellular mechanisms of myocardial failure [J]. Am J Cardiol, 1997, 80: 15-25.
6Leonetli G, Crspidi C. Choosing the right ACE inhibitor, A guide to selection [J]. Drugs, 1995, 49: 516-535.
7The cardiac Insufficienay Bisoprolol Study Ⅱ(CIBIS-Ⅱ):a randomised trial[J].Lancet,1999,353(9146):9-13.
8Bristow MR,Gilbort KM,Abraham,et al.Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic Heart Failure MOCHA.Investingators[J].Circulation,1996,94(11):2807-2816.
9Packer M,Coluai WS,Sackner-kernstein JD,et al.Double-blind,placebo-controled study of the effects of carvedilol in patients with moderate to severe heart failure.The Precise Trial.Prospective.Randomized.Evaluation of cavedilol on symptoms and Exercise[J].Circulation,1996,94(11):2793-2799.
